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Abstract
Introduction: Although renal replacement therapy (RRT) is a common procedure in critically ill patients with acute
kidney injury (AKI), its efficacy remains uncertain. Patients who receive RRT usually have higher mortality rates than
those who do not. However, many differences exist in severity patterns between patients with and those without
RRT and available results are further confounded by treatment selection bias since no consensus on indications for
RRT has been reached so far. Our aim was to account for these biases to accurately assess RRT efficacy, with
special attention to RRT timing.
Methods: We performed a propensity analysis using data of the French longitudinal prospective multicenter
Outcomerea database. Two propensity scores for RRT were built to match patients who received RRT to controls
who did not despite having a close probability of receiving the procedure. AKI was defined according to RIFLE
criteria. The association between RRT and hospital mortality was examined through multivariate conditional logistic
regression analyses to control for residual confounding. Sensitivity analyses were conducted to examine the impact
of RRT timing.
Results: Among the 2846 study patients, 545 (19%) received RRT. Crude mortality rates were higher in patients
with than in those without RRT (38% vs 17.5%, P < 0.001). After matching and adjustment, RRT was not associated
with a reduced hospital mortality. The two propensity models yielded concordant results.
Conclusions: In our study population, RRT failed to reduce hospital mortality. This result emphasizes the need for
randomized studies comparing RRT to conservative management in selected ICU patients, with special focus on
RRT timing.
Introduction
Acute kidney injury (AKI) significantly contributes to
the morbidity and the mortality of critically ill patients
through metabolic derangements, fluid overload and
harmful effects of these disturbances on other failing
organs. Renal replacement therapy (RRT), although not
achieving the same level of homeostasis as a normally
functioning kidney, helps limit the consequences of AKI
and allows adequate administration of fluids and nutri-
tional support. However, its benefits (aside from life-
threatening complications, such as severe hyperkalemia,
pulmonary edema, and intractable acidosis) in critically
ill patients with AKI remain unclear.
Available data are derived from uncontrolled studies,
which all showed higher mortality rates among popula-
tions treated with RRT [1-5]. Due to their design, how-
ever, confounders and biases may have limited their
accuracy. Particularly, treatment selection bias [6] may
have confounded the results. This kind of bias occurs
when no agreed-upon indications exist for a given treat-
ment or procedure, which is the case for RRT despite
the recent publication of recommendations for the pre-
vention and management of AKI in the intensive care
unit (ICU) [7]. Since there are no clear guidelines about
whether and when RRT should be started, patients’
characteristics, in-ICU events, and other aspects of ICU
* Correspondence: christophe.clech@avc.aphp.fr
1Medical-surgical ICU, Avicenne Teaching Hospital, 125 route de Stalingrad,
Bobigny, 93000, France
Full list of author information is available at the end of the article
Clec’h et al. Critical Care 2012, 16:R236
http://ccforum.com/content/16/6/R236
© 2012 Clec’h et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
care, which may also affect outcomes, may confound the
analysis of RRT efficacy, leading to inconclusive results.
The propensity score technique described by Rosen-
baum and Rubin is a powerful method to control for
treatment selection bias [8,9]. The aim of this study was
to use the propensity technique to estimate the associa-
tion of RRT with in-hospital mortality in ICU patients
with AKI.
Materials and methods
Study design and data source
We conducted an observational study in a multiple-center
database (OUTCOMEREA) from January 1997 to June
2009. Methods of data collection and quality of the data-
base have been described in details elsewhere [10]. Briefly,
a large set of data on a random sample of patients older
than 16 years with ICU stays longer than 24 h was pro-
spectively collected by the senior physicians of the partici-
pating ICUs and entered into the database each year. The
quality control procedure involved multiple automatic
checking of internal consistency and biennial audits.
Ethics approval
In accordance with French law, the OUTCOMEREA
database was declared to the Commission Nationale de
l’Informatique et des Libertés. The study was approved
by the ethics committee of Clermont-Ferrand, France.
Since the study did not modify patients’ management
and data were processed anonymously, the need for
informed consent was waived.
Study population and definitions
All patients in the database were eligible. Exclusion cri-
teria were: chronic kidney disease (CKD) (with or with-
out complete loss of kidney function), pre-renal cause of
renal dysfunction (that is rapidly reversible functional
renal failure), multiple ICU stays, decision to withhold
or withdraw life-sustaining treatments, and renal repla-
cement therapy for extra-renal indications (such as,
intoxications or cardiogenic shock). CKD was defined
either according to the Acute Physiology and Chronic
Health Evaluation (APACHE) II definition or a specific
code in the database when not requiring dialysis. Pre-
renal cause of renal dysfunction was also identified
through a specific code in the database. The reason for
excluding these patients was that their prognosis may be
different from that of patients with prior normal renal
function who present a non-rapidly reversible cause of
AKI. Patients with multiple ICU stays, or with a decision
to withhold or withdraw life-sustaining treatments, were
also excluded to avoid confusion in the assessment of
hospital mortality.
Among the remaining patients, those in whom AKI
occurred were analyzed. AKI was defined according to
the RIFLE (Risk, Injury, Failure, Loss and End-stage
renal failure) criteria [11], and patients were classified
according to the maximum RIFLE class (Risk, Injury or
Failure) reached during their ICU stay. The maximum
RIFLE class was determined before RRT initiation in
patients who received RRT and whenever during the
ICU stay in patients who did not. Since the 6- and 12-h
urine outputs were not recorded in the database, we
used the glomerular filtration rate (GFR) only. The GFR
criteria were determined according to changes in serum
creatinine from baseline values. As AKI may be present
on ICU admission in a high proportion of patients, we
chose to assess baseline creatinine values using the
Modification of Diet in Renal Disease (MDRD) equation.
As recommended by the Acute Dialysis Quality Initia-
tive Group, a normal GFR of 75 ml/min/1.73 m2 before
ICU admission was assumed [11].
RRT consisted of intermittent hemodialysis or contin-
uous veno-venous hemofiltration/hemodiafiltration. All
participating centers were able to provide both techni-
ques of RRT. The decision to start RRT was left at the
discretion of the attending ICU physicians.
Data collection
The following data were recorded:
• baseline characteristics on ICU admission: age, sex,
McCabe class (class 1, no fatal underlying disease; class
2, underlying disease fatal within five years; class 3,
underlying disease fatal within one year), Simplified
Acute Physiology Score (SAPS) II, comorbidities
assessed according to the APACHE II definitions, trans-
fer from ward (defined as a stay in an acute-bed ward
≥24 hrs immediately before ICU admission), and admis-
sion category (medical, scheduled surgery, or unsched-
uled surgery),
• during the ICU stay: daily biological parameters
(blood urea nitrogen, serum creatinine, kaliemia), daily
urine output, daily weight, time from admission to max-
imum RIFLE class, time to RRT, daily Sequential Organ
Failure Assessment (SOFA) score, and modified SOFA
score (mSOFA, SOFA - specific renal component),
• on ICU discharge: renal status (recovery or need for
prolonged renal support), and length of ICU stay, and,
• on hospital discharge: vital status.
Endpoints
The primary endpoint was hospital mortality.
The secondary endpoints were the length of ICU stay,
and renal status on ICU discharge.
Propensity technique
Since RRT was not randomly assigned in our study
population, treatment selection bias was accounted for
by using the propensity technique. When building a
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propensity score, the main risk is the omission of an
important variable in the propensity regression. Thus,
we fitted and compared two different models to
strengthen our analysis. As recommended, propensity
scores were determined through multivariate logistic
regression [12], in which RRT was the dependent vari-
able. Independent variables were related to the probabil-
ity of receiving the treatment and also outcome in order
to reduce both the bias and the variance in the estima-
tion of treatment effect [13,14]. Independent variables
introduced in model 1 were: rising creatinine reflected
by maximum RIFLE class, oliguria reflected by the 24-h
urine output on reaching maximum RIFLE class, and
SAPS II score. Independent variables introduced in
model 2 were: blood urea nitrogen, serum creatinine
and kaliemia measured on reaching maximum RIFLE
class (that is, before RRT was started), fluid accumula-
tion (reflected by the difference between patients’ weight
recorded on reaching maximum RIFLE class and that
recorded on ICU admission), and SAPS II score.
Using an algorithm [15], we matched patients who
received RRT during their ICU stay to other AKI
patients who did not on the basis of each of the two
propensity scores that we built (model 1 and model 2).
Specifically, we sought to match each patient with RRT
up to three controls who had the closest propensity
score (within 0.05 on a scale of 0 to 1).
Besides, patients were also matched on center and
period of admission to account for possible inconsistent
institutional practices or changes in RRT practices over
time. Age (+/- 5 years) was the final matching criterion.
The adequacy of the propensity scores in controlling for
treatment selection bias was demonstrated by testing for
differences between matched patients in biological para-
meters likely to trigger RRT on reaching maximum
RIFLE class.
The goodness of fit and the discrimination of the two
logistic regression models used to derive a propensity
score for RRT were evaluated by the Hosmer-Lemeshow
(HL) test, and the c statistic (area under the receiver
operating characteristics curve), respectively.
Statistical analyses
Results are expressed as numerical values and percen-
tages for categorical variables, and as means and stan-
dard deviations (SD) or medians and quartiles [Q1-Q3]
for continuous variables.
In the whole cohort, comparisons of patients with and
those without RRT were based on chi-square tests for
categorical data, and on Student’s t-test or Wilcoxon’s
test for continuous data, as appropriate.
Comparisons between matched patients were based on
univariate conditional logistic regression. Multivariate
conditional logistic regression analysis was used to
examine the association between RRT and subsequent
hospital mortality, adjusting for variables potentially
related to mortality that were not considered in the pro-
pensity regression (namely baseline characteristics that
had a P value < 0.1 in univariate analysis, and the modi-
fied SOFA score (SOFA score - specific renal compo-
nent) computed on the day maximum RIFLE class was
reached).
Sensitivity analyses were performed to test whether
any delay in RRT initiation could affect patients’ prog-
nosis. For that purpose, the timing of RRT was divided
into three classes (less than 24 h, between 24 and 48 h,
greater than 48 h after reaching maximum RIFLE class).
Since the use of the MDRD equation to estimate base-
line creatinine values has not been validated in ICU
patients, we also performed sensitivity analyses that
included only patients with a normal serum creatinine
value measured on ICU admission.
Wald c2 tests were used to determine the significance
of each variable. Adjusted odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated for each para-
meter estimate.
Analyses were computed using the SAS 9.1 software
package (SAS Institute, Cary, NC, USA).
Results
Study patients
Over the study period, 10,911 patients with a single ICU
stay were screened, of whom 2,272 were excluded for
the following reasons: decision to withhold or withdraw
life-sustaining treatments (n = 1,378, 12.6%), history of
chronic kidney disease (n = 672, 6.2%), functional renal
failure (n = 176, 1.6%), and RRT for extra-renal indica-
tions (n = 46, 0.4%).
Among the remaining 8,639 patients, 2,846 (32.9%)
had AKI (1,025 (36%) R class patients, 830 (29.2%) I
class patients, and 991 (34.8%) F class patients).
RRT was initiated in 545 (19.1%) AKI patients (41
(7.5%) R class patients, 110 (20.2%) I class patients, and
394 (72.3%) F class patients).
Patients who received RRT were younger, had higher
severity scores, were more likely to be transferred from
ward, and presented more comorbidities than patients
who did not receive RRT (Table 1). Differences between
patients with and without RRT according to the maxi-
mum RIFLE class reached during the ICU stay are
shown in Additional files 1, 2, and 3.
Dynamics of AKI and timing of renal replacement therapy
AKI occurred early in the course of ICU stay. Three-
quarters of the patients reached their maximum RIFLE
within three days after ICU admission.
When a decision of RRT was made, RRT was started
less than 48 h after reaching maximum RIFLE class in
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479/545 (87.9%) patients. Continuous veno-venous
hemofiltration/hemodiafiltration and intermittent hemo-
dialysis were used as initial RRT modality in 345 (63.3%)
patients and 200 (36.7%) patients, respectively.
Details on timings of AKI and RRT for each RIFLE
class are shown in Tables 2 and 3.
Differences in parameters (measured on reaching max-
imum RIFLE class) likely to trigger RRT between
patients who actually received RRT and those who did
not are presented in Table 4. Patients with RRT had
higher blood urea nitrogen, serum creatinine and kalie-
mia but their pH values were not significantly lower.
Matching on the propensity scores
The two propensity models showed satisfying goodness
of fit and discrimination (P values for the HL test: 0.39
and 0.52, c statistics: 0.80 and 0.78, in models 1 and 2,
respectively). The percentage of matched patients was
high despite numerous and strict matching criteria. In
model 1, 383/545 (70%) patients who received RRT
could be matched to 726 controls who did not receive
RRT. In model 2, 376/545 (69%) RRT patients could be
matched to 754 controls. In both models, there were no
differences between patients with and those without
RRT in biological parameters likely to trigger RRT on
reaching maximum RIFLE class (Table 5), thus confirm-
ing the ability of the propensity scores to control for
treatment selection bias. However, there remained dif-
ferences in SAPS II, mSOFA, urine output and fluid
accumulation that were thus adjusted for (Table 5).
Impact of renal replacement therapy
RRT resulted in longer lengths of ICU stay after reach-
ing maximum RIFLE class (see Additional files 4 and 5)
but did not reduce mortality. Crude hospital mortality
rates of patients with and without RRT were 45.1% and
Table 1 Baseline characteristics of acute kidney injury (AKI) patients with and without renal replacement therapy
(RRT).
Variable Patients with RRT
(N = 545)
Patients without RRT
(N = 2301)
P value
Age, mean (SD) 61.3 (16.6) 67.6 (15.5) < 0.0001
Males, no. (%) 363 (66.6) 1309 (59.9) < 0.0001
SAPS II score, mean (SD) 56.8 (19.2) 48.6 (19.8) < 0.0001
APACHE II score, mean (SD) 21.4 (7.0) 19.6 (7.1) < 0.0001
Transfer from ward, no. (%) 291 (53.4) 1072 (46.6) 0.004
McCabe, no. (%)
1 314 (57.6) 1352 (58.8)
2 188 (34.5) 771 (33.5) 0.88
3 43 (7.9) 178 (7.7)
Admission category, no. (%)
Medical 388 (71.2) 1655 (71.9)
Scheduled surgery 52 (9.5) 259 (11.3) 0.25
Unscheduled surgery 105 (19.3) 387 (16.8)
Chronic coexisting conditions, no. (%)
Cardiac disease 89 (16.3) 420 (18.3) 0.29
Respiratory disease 55 (10.1) 311 (13.5) 0.03
Liver disease 50 (9.2) 128 (5.6) 0.002
Immunodeficiency 104 (19.1) 336 (14.6) 0.01
Uncomplicated diabetes mellitus 63 (11.6) 257 (11.2) 0.79
Complicated diabetes mellitus 30 (5.5) 118 (5.1) 0.72
SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation.
Table 2 Timing of acute kidney injury (AKI).
All
patients
R class
patients
I class
patients
F class
patients
Time to AKI onset* 2 [1-2] 1 [1-2] 2 [1-2] 1 [1-2]
Time to maximum RIFLE
class*
2 [1-3] 1 [1-2] 2 [1-3] 2 [1-3]
Results are expressed as medians (in days) and [interquartile range]. *From
ICU admission (day 0).
Table 3 Timing of renal replacement therapy initiation.
All
patients
R class
patients
I class
patients
F class
patients
Time from AKI onset 1 [0-3] 0 [0-1] 1 [0-2] 1 [0-3]
Time from maximum RIFLE
class
0 [0-1] 0 [0-1] 0 [0-1] 0 [0-1]
Results are expressed as medians (in days) and [interquartile range]. AKI, acute
kidney injury.
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23.4%, respectively (P < 0.001). Among patients who
received RRT, 92 of the 338 survivors (27.2%) still
needed renal support on ICU discharge.
After matching on the propensity scores, patients who
received RRT still had higher mortality rates than their
respective controls (model 1: 38.9% vs 22.2%, P < 0.001;
model 2: 38% vs 18.3%, P < 0.001), in univariate analysis.
After adjustment on confounding variables, RRT was
not associated with a reduced hospital mortality, what-
ever its timing (Table 6). Additional files 6 and 7 show
details according to the maximum RIFLE class reached
during the ICU stay.
The sensitivity analyses that included only patients
with a normal serum creatinine value measured on ICU
admission yielded similar results as the full analysis
(Additional file 8).
Discussion
While the impact of RRT modalities has been widely
investigated through randomized controlled trials
[16-21], the overall efficacy of RRT remains uncertain.
Actually, there is no real head-to-head comparison of
AKI patients with and without RRT in the current lit-
erature. Mortality rates are usually higher in patients
with than in those without RRT [1-5]. However, no defi-
nitive conclusions can be can be drawn from these data
due to the absence of clear indications for RRT and the
many differences in severity patterns between patients
who receive RRT and those who do not. In other words,
treatment selection bias and patients’ underlying severity
are major confounders making the assessment of RRT
efficacy challenging.
Our study brings a new insight in the field. By using
the propensity technique, we were able to compare hos-
pital mortality rates in matched patients with and with-
out RRT, having a close probability of receiving RRT
(somewhat as though RRT had been ‘randomly
assigned’). Moreover, since the SAPS II score was
included in the propensity regressions, matched patients
with and without RRT had also a similar predicted
Table 4 Differences in parameters likely to trigger renal
replacement therapy (RRT) on reaching maximum RIFLE
class between patients with and without RRT (whole
cohort).
Patients with
RRT
N = 545
Patients without
RRT
N = 2301
P value
Urea (mmol/L) 20 [14-28] 14 [10-20] < 0.001
Creatinine (mmol/L) 305 [231-408] 178 [143-247] < 0.001
Potassium (mmol/L) 4.3 [3.8-5.1] 4.2 [3.7-4.7] < 0.001
pH 7.34 [7.24-7.43] 7.36 [7.27-7.44] 0.4
mSOFA 7 [4-10] 5 [2-7] < 0.001
SAPS II 49 [38-62] 41 [32-53] < 0.001
Urine output (L) 0.4 [0.1-1.1] 1.3 [0.6-2.3] < 0.001
Fluid accumulation
(L)
4 [2-8] 2 [0-4] < 0.001
Results are expressed as medians and [interquartile range]. SOFA, Sequential
Organ Failure Assessment; mSOFA, SOFA - specific renal component; SAPS,
Simplified Acute Physiology Score.
Table 5 Differences in parameters likely to trigger renal
replacement therapy (RRT) on reaching maximum RIFLE
class between patients with and without RRT (matched
patients).
Patients with
RRT
Patients without
RRT
P value
Model 1 N = 383 N = 726
Urea (mmol/L) 15 [10-23] 15 [11-24] 0.3
Creatinine (mmol/L) 217 [158-281] 214 [158-271] 0.4
Potassium (mmol/L) 4.1 [3.6-4.7] 4.1 [3.6-4.6] 0.9
pH 7.34 [7.24-7.44] 7.36 [7.28-7.44] 0.5
mSOFA 7 [5-9] 5 [3-8] < 0.001
SAPS II 50 [38-62] 43 [34-56] < 0.01
Urine output (L) 0.6 [0.2-1.3] 1.4 [0.7-2.5] < 0.001
Fluid accumulation
(L)
4 [2-8] 2 [0-6] < 0.01
Model 2 N = 376 N = 754
Urea (mmol/L) 16 [10-23] 14 [10-22] 0.9
Creatinine (mmol/L) 217 [158-286] 203 [144-265] 0.12
Potassium (mmol/L) 4.1 [3.6-4.8] 4.1 [3.6-4.6] 0.4
pH 7.33 [7.24-7.43] 7.36 [7.27-7.45] 0.3
mSOFA 7 [5-10] 5 [3-8] < 0.001
SAPS II 50 [39-63] 42 [34-54] < 0.001
Urine output (L) 0.6 [0.2-1.2] 1.2 [0.5-2.2] < 0.001
Fluid accumulation
(L)
4 [2-8] 2 [1-6] < 0.03
Results are expressed as medians and [interquartile range]. SOFA, Sequential
Organ Failure Assessment; mSOFA, SOFA - specific renal component; SAPS,
Simplified Acute Physiology Score.
Table 6 Association of renal replacement therapy (RRT)
with hospital mortality in multivariate conditional
logistic regression (matched patients) according to
timing of RRT.
OR 95% CI P value
Model 1
All RRT (whatever the timing) 1.30 0.96-1.78 0.09
Immediate RRT* 1.43 0.91-2.22 0.12
Early RRT** 0.99 0.45-2.15 0.92
Delayed RRT*** 2.37 1.04-5.40 0.04
Model 2 -
All RRT (whatever the timing) 1.41 1.02-1.94 0.04
Immediate RRT* 1.14 0.71-1.81 0.59
Early RRT** 2.31 0.96-5.67 0.06
Delayed RRT*** 2.29 1.05-4.99 0.04
OR, odds ratio; CI, confidence interval. *Initiated within 24 h after reaching
maximum RIFLE class; **initiated between 24 and 48 h after reaching
maximum RIFLE class; ***initiated more than 48 h after reaching maximum
RIFLE class.
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hospital mortality. Consequently, the risk of biased
assessment of the association between RRT and hospital
mortality was minimized.
Like in the interesting study of Elseviers et al. [22]
that reported an increased risk of death for RRT com-
pared to conservative treatment in ICU patients after
extensive adjustment on disease severity, we failed to
demonstrate any beneficial effect of RRT. While it can-
not be totally run out that RRT per se is potentially
harmful (hemodynamic instability, central venous cathe-
ter-related blood stream infections, inflammation and
coagulation disorders, which are common complications
of RRT, may well have outweighed its metabolic bene-
fits), these results emphasize the need for a critical reap-
praisal of current RRT practices and definitions of AKI.
Particularly, it must be kept in mind that timing of RRT
initiation is undoubtedly a key issue. In this regard, a
plausible explanation for our findings is that RRT was in
fact initiated too late. Actually, patients were classified
according to the glomerular filtration rate (GFR) criteria
of RIFLE whereas increases in serum creatinine often
lag behind the true reduction in GFR. Thus, although
RRT was in place within 24 h after reaching maximum
RIFLE class in the vast majority of patients, it might
well have been initiated at a more advanced stage of
renal dysfunction than clinically appreciated. So, our
results do not imply, as one may believe at first sight,
that RRT should be abandoned. Rather, the key message
could be: ‘initiate RRT as early as possible’. That
patients who received RRT had more coexisting organ
failures on reaching maximum RIFLE class than their
matched controls lends support to this hypothesis of
delayed AKI diagnosis and RRT. Since initiation of RRT
when multiple organ failures are present probably limits
its ability to improve patients’ outcomes, the utilization
of highly sensitive and early diagnostic biomarkers such
as cystatin C or neutrophil gelatinase-associated lipoca-
lin (instead of serum creatinine) as triggers for RRT is
worth considering for future investigations in the ICU
[23-30].
Despite the use of an original statistical approach
minimizing the risk of bias, our study has potential lim-
itations that merit consideration.
First, residual confounding cannot be totally excluded
because of the observational design. However, by apply-
ing the propensity technique and matching on age, and
center and period of admission, we dealt with confound-
ing more extensively than in prior reports. Besides, that
the two propensity models yielded similar results made
the hypothesis of having omitted an important con-
founding variable unlikely.
Second, we encountered the same problem as others
[31,32]: the 6- and 12-h urine outputs were not
recorded in our database. Therefore, patients were
classified according to the GFR criteria only. Patients
classified according the GFR criteria seem to be more
severely ill and have slightly higher mortality rates than
their counterparts classified according to the urine out-
put criteria [33,34]. Having considered both criteria may
have resulted in a different estimation of RRT efficacy.
Yet, urine output does not differentiate functional (pre-
renal) AKI from organic AKI and new serum or urine
biomarkers are probably much more reliable for the
early diagnosis of AKI.
Third, the MDRD equation used to estimate baseline
creatinine values has not been validated in ICU patients.
Nevertheless, the sensitivity analysis including only data
from patients with a normal serum creatinine value on
ICU admission yielded similar results as the full analysis,
showing that the use of the MDRD equation did not
bias the results.
Fourth, the use of the MDRD equation to estimate
baseline creatinine values refrains from precisely estab-
lishing AKI onset (that is, patients with an apparent
early-onset AKI may in fact have developed AKI for sev-
eral days before ICU admission). This could be proble-
matic in that the prognosis of early AKI may differ from
that of late AKI. That results of the sensitivity analysis,
including only data from patients with a normal serum
creatinine value on ICU admission, yielded similar
results as the full analysis runs counter to the hypothesis
of differential prognosis and impact of RRT between
early and late AKI. However, this issue needs further
evaluation.
Fifth, it might be argued that RRT initiation may have
prevented R or I class patients from reaching a higher
RIFLE class (thus leading to an underestimation of their
degree of renal dysfunction, and subsequent comparison
of RRT patients with non-RRT patients having a more
severe renal dysfunction). Yet, this limit, which is inher-
ent to the RIFLE classification, does not apply to F class
patients. Since odds ratios of mortality associated with
RRT in the whole population were similar as those in
the F class patients, it is very unlikely that results were
flawed by a potential misclassification bias induced by
an underestimation of renal dysfunction in RRT
patients.
Sixth, the prognostic impact of the dose and initial
modality of RRT was not assessed. It must be empha-
sized, however, that all randomized controlled trials
conducted so far have showed equivalence between high
and low doses, and continuous and intermittent RRT
[16-21].
Finally, data on the long-term impact of AKI and RRT
were not recorded in the database, and concomitant
measures likely to prevent or positively influence the
course of renal dysfunction (optimization of hemody-
namics and renal perfusion, avoidance of nephrotoxic
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drugs) were not analyzed. These issues deserve future
prospective evaluations.
Conclusions
Together with those of Elseviers et al. [22], our findings
raise concern about the actual efficacy of RRT. Of
course, these results must be cautiously interpreted
since the assessment of RRT efficacy through observa-
tional data is very challenging. However, they emphasize
the need for a critical reappraisal of current RRT prac-
tices. Large randomized controlled trials comparing
RRT to conservative management in selected ICU
patients with AKI, and focusing on RRT timing, are
urgently warranted to provide definite conclusions.
Key messages
• Aside from life-threatening conditions, evidence
supporting the use of renal replacement therapy
(RRT) in critically ill patients with acute kidney
injury (AKI) is lacking. Currently available data on
RRT efficacy exclusively stem from observational
studies, whose results may have been confounded by
treatment selection bias and differences in patients’
severity.
• In this study, we extensively dealt with confound-
ing by using the propensity score technique and
multivariate regression models to provide an as
accurate as possible estimation of RRT efficacy.
• RRT was not associated with decreased mortality
and even seemed to impair patients’ outcome when
initiated too late.
• These results emphasize the need for further ran-
domized studies comparing RRT to conservative
management in selected ICU patients, with special
focus on RRT timing.
Additional material
Additional file 1: Baseline characteristics of RIFLE R class patients
with and without renal replacement therapy (RRT).
Additional file 2: Baseline characteristics of RIFLE I class patients
with and without renal replacement therapy (RRT).
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with and without renal replacement therapy (RRT).
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class in patients with and without renal replacement therapy (RRT).
Additional file 5: Lengths of ICU stay after reaching maximum RIFLE
class in nonsurvivors with and without renal replacement therapy
(RRT).
Additional file 6: Association of renal replacement therapy (RRT)
with hospital mortality in multivariate conditional logistic
regression according to timing of RRT and maximum RIFLE class
reached during the ICU stay (model 1).
Additional file 7: Association of renal replacement therapy (RRT)
with hospital mortality in multivariate conditional logistic
regression according to timing of RRT and maximum RIFLE class
reached during the ICU stay (model 2).
Additional file 8: Association of renal replacement therapy (RRT)
with hospital mortality in multivariate conditional logistic
regression (matched patients) according to timing of RRT: results of
sensitivity analyses including only patients with a normal serum
creatinine value measured on ICU admission.
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